Equities analysts expect Strongbridge Biopharma PLC (NASDAQ:SBBP) to post $1.77 million in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Strongbridge Biopharma PLC’s earnings. The lowest sales estimate is $1.20 million and the highest is $2.35 million. The company is expected to announce its next quarterly earnings report on Friday, December 22nd.

On average, analysts expect that Strongbridge Biopharma PLC will report full-year sales of $1.77 million for the current financial year, with estimates ranging from $4.64 million to $6.95 million. For the next year, analysts forecast that the company will post sales of $14.04 million per share, with estimates ranging from $9.39 million to $21.91 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Strongbridge Biopharma PLC.

Strongbridge Biopharma PLC (NASDAQ:SBBP) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.34) earnings per share for the quarter, hitting the consensus estimate of ($0.34). The firm had revenue of $1.53 million for the quarter, compared to the consensus estimate of $0.84 million.

SBBP has been the topic of a number of recent research reports. Zacks Investment Research raised Strongbridge Biopharma PLC from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a research report on Wednesday, July 19th. ValuEngine raised Strongbridge Biopharma PLC from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. Finally, Oppenheimer Holdings, Inc. assumed coverage on Strongbridge Biopharma PLC in a report on Thursday, August 10th. They set an “outperform” rating and a $12.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $11.81.

COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Expect Strongbridge Biopharma PLC (SBBP) Will Post Quarterly Sales of $1.77 Million” was reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/25/zacks-brokerages-expect-strongbridge-biopharma-plc-sbbp-will-post-quarterly-sales-of-1-77-million.html.

Institutional investors and hedge funds have recently modified their holdings of the stock. State of Wisconsin Investment Board purchased a new stake in Strongbridge Biopharma PLC during the 2nd quarter worth about $114,000. Rhumbline Advisers bought a new position in Strongbridge Biopharma PLC in the 2nd quarter worth about $154,000. California State Teachers Retirement System bought a new position in Strongbridge Biopharma PLC in the 2nd quarter worth about $277,000. Teachers Advisors LLC bought a new position in Strongbridge Biopharma PLC in the 2nd quarter worth about $297,000. Finally, Bank of New York Mellon Corp bought a new position in Strongbridge Biopharma PLC in the 2nd quarter worth about $331,000. 56.53% of the stock is currently owned by institutional investors and hedge funds.

Strongbridge Biopharma PLC (NASDAQ:SBBP) traded down 1.59% on Wednesday, reaching $6.20. The company’s stock had a trading volume of 63,272 shares. Strongbridge Biopharma PLC has a 12 month low of $2.00 and a 12 month high of $8.85. The firm has a 50 day moving average of $6.57 and a 200 day moving average of $5.88. The firm’s market cap is $219.08 million.

About Strongbridge Biopharma PLC

Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis.

Get a free copy of the Zacks research report on Strongbridge Biopharma PLC (SBBP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Strongbridge Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.